TARGETED THERAPY ADAPTED TO TUMOR BIOLOGY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA OR HEPATOCHOLANGIOCARCINOMA REFRACTORY TO ATEZOLIZUMAB/BEVACIZUMAB

<div><p><b><span data-contrast="auto">Background</span></b><span data-contrast="auto">: The “French Medicine Genomic program 2025” is an academic research program that allows to perform whole-genome/exome/RNA sequencing in advanced cancer refractory to systemic treatments to give access to off-labeled therapies adapted to genomic alterations in clinical practice. We reported results in intermediate and advanced hepatocellular carcinoma (HCC) and hepato-cholangiocarcinoma (H-CCK).

EMPAGLIFLOZIN IS EQUALLY EFFECTIVE IN REDUCING LIVER FAT CONTENT IN T2DM PATIENTS AND IN NON-DIABETIC INDIVIDUALS, A RANDOMIZED TRIAL

<div><p><b>Background:</p> </b><p style="font-weight: 400;">This study was performed to examine the effect of empagliflozin on liver fat content in T2DM patients and in nondiabetic individuals, and the relationship between the decrease in liver fat and other metabolic actions of empagliflozin.</p>

ABILITY OF SECOND HARMONIC GENERATION/TWO-PHOTON EXCITATION FLUORESCENCE IMAGING AND AI ANALYSIS TO DETECT AND QUANTIFY DRUG-INDUCED, PARAMETER-LEVEL CHANGES OF FIBROSIS: RESULTS FROM THE FALCON-1 CLINICAL TRIAL

<div><p><b>Background: </b>FDA recommended histopathological end-points for NASH clinical trials may not be fully evaluated by conventional histological staging. Shorter time frames in NASH trials make it difficult to assess changes in treatment-induced fibrosis with current classification systems. Assessment of specific morphological fibrosis parameters and their quantification in specific zones of NASH-CRN classification, can be done by SHG/TPE-based AI platforms.

INDIVIDUAL PRURITUS AND BILE ACID RESPONSES OVER TIME WITH ODEVIXIBAT TREATMENT: POOLED DATA FROM THE PHASE 3 ASSERT AND ASSERT-EXT STUDIES IN PATIENTS WITH ALAGILLE SYNDROME

<div><p><b>Background: </b>Alagille syndrome (ALGS) is a rare, genetic, multisystem disorder in which cholestatic liver disease is common and that may include clinical manifestations of severe pruritus and elevated bile acids (BAs). The efficacy and safety of odevixibat, an ileal bile acid transporter inhibitor, were assessed in patients with ALGS in the phase 3 ASSERT and ASSERT-EXT trials. Using data from these studies, we analyzed the effects of odevixibat on pruritus and BAs over time.</p>

LONG TERM HBsAg REDUCTION BY A NASAL ADMINISTRATIVE THERAPEUTIC VACCINE CONTAINING HBsAg AND HBCAG MIXED WITH MUCOADHESIVE CVP IN PATIENTS WITH CHRONIC HBV INFECTION: THE RESULTS OF 48 MONTHS FOLLOW UP

<div><p><b>Background: </b>We reported the HBsAg reduction by a nasal administrative therapeutic vaccine containing HBsAg/HBcAg mixed with mucoadhesive excipient carboxy-vinyl polymer (CVP-NASVAC) in chronically HBV infected patients. This study was aimed to assess the long-term efficacy of CVP-NASVAC at 48 months after the first 10 doses.</p>

EFFECTIVENESS AND SAFETY OF SECOND-LINE THERAPY IN PRIMARY BILIARY CHOLANGITIS (PBC): A PROSPECTIVE MULTICENTER REAL-WORLD COHORT.

<div><p><b>Background: </b>About 30% of patients with PBC have a suboptimal response to ursodeoxycholic acid (UDCA), leading to a worse prognosis. In the phase III POISE trial, response to obeticholic acid (OCA) was assessed by using the POISE score. Recently, complete biochemical normalization (normal ALP and bilirubin ≤ 0.6 ULN) has been proposed as a new therapeutic aim in PBC, as it significantly improves liver-related and overall survival, but the effectiveness of second-line therapy for this new therapeutic target has not been evaluated.</p>

PREOPERATIVE HEPATOLOGY AND PRIMARY CARE VISITS ARE ASSOCIATED WITH REDUCED POSTOPERATIVE MORTALITY IN PATIENTS WITH CIRRHOSIS UNDERGOING SURGERY: A VETERANS AFFAIRS PROPENSITY MATCHED STUDY

<div><p><b>Background:<span> </b>Patients with cirrhosis have increased surgical risk compared to the general population. Preoperative optimization by nonsurgical clinicians improves postoperative outcomes after colectomy in studies of patients with major comorbidities, however, data specific to patients with cirrhosis and addressing more diverse surgeries are limited.

SPLEEN STIFFNESS MEASUREMENT BY TRANSIENT ELASTOGRAPHY WITH A SPLEEN-DEDICATED MODULE: A PROSPECTIVE PILOT FEASIBILITY STUDY IN A PEDIATRIC COHORT

<div><p><strong><b>Background:</strong> </b>Several studies in adults showed that spleen stiffness measurement (SSM) by vibration-controlled transient elastography (VCTE) can accurately assess clinically significant portal hypertension (HTN) and predict presence of esophageal varices. However, pediatric studies on SSM published thus far have used a liver-specific probe to measure the spleen making them difficult to interpret and possibly overestimating SSM, as the spleen is inherently a stiffer organ than the liver.

CHOLANGIOCYTE-MEDIATED INFILTRATION OF NEUTROPHILS IN THE PERI-PORTAL REGION INDUCES OXIDATIVE STRESS IN PRIMARY SCLEROSING CHOLANGITIS

<div><p><b>Background:</p> </b><p>Primary Sclerosing Cholangitis (PSC) manifests with fibrotic scarring of the intrahepatic and extrahepatic bile ducts due to an immune-mediated inflammatory response. The cyclic GMP–AMP synthase –stimulator of interferon genes (cGAS-STING) signaling pathway is a key mediator of inflammatory gene expression and cytokine release in response to cellular stress. The inflammatory milieu observed in PSC recruits immune cells, including neutrophils, to infiltrate the peri-portal region.

Subscribe to